Payers pre-commit to cover off-label generics when a definitive trial is positive
Even when a trial proves a cheap old drug helps, insurers may refuse to pay because it is not licensed for cancer. A standing promise to pay would remove that fear.
Uncertainty about reimbursement discourages trialists and clinicians and leaves proven repurposed treatments unused. The proposal is a formal coverage policy, adopted by public payers and large insurers, stating that any off-patent drug shown in a registration-quality randomised trial to improve survival or a validated patient-relevant endpoint in cancer will be covered for that use within six months of publication, subject to an independent evidence review, regardless of label status. The policy is published in advance so trial funders can rely on it.
- No incentive to repurpose cheap drugs · Old, cheap drugs with anti-cancer signals never get the trials they need because no one profits from the result.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
Pages like this
not linked directly; found by shared links- IdeaThree years of indication-specific exclusivity for proving a new cancer use of an old drug
Shares No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
- IdeaA $50 million prize for the first off-patent drug proven to extend cancer survival
Shares No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
- IdeaA public fund and label pathway to trial generic drugs against cancer
Shares No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
- IdeaA repurposing label pathway with short exclusivity that non-profits can hold
Shares No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
- IdeaPatent-free open-source development of repurposed and off-patent cancer drugs
Shares No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.